Abbott Laboratories stock is part of a healthcare portfolio exposed to medical technology, diagnostics and pharmaceutical ...

Abbott Laboratories has seen a mixed share price record in recent years, which raises a straightforward question for anyone ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q3 2026, with sales up 14.5% year on year to $13.01 ...

Abbott Laboratories plans to spin off its nutrition business into a separate company – a move that follows years of tumult over its infant formulas. The new business will sell Abbott products ...

This company has delivered earnings and dividend growth over time. Abbott’s innovation and a new acquisition could spur more growth in the years to come. 10 stocks we like better than Abbott ...

Abbott Laboratories added a major portfolio decision to its third-quarter update on October 21, 2026: The company intends to ...

Shares in Abbott Laboratories ($ABT) were down 4% in pre-market trading today as it announced that it planned to separate its global Nutrition business into an ...

Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition ...

Abbott Laboratories is now fairly valued after a 26% decline from its 2021 highs, but I maintain a Hold rating. ABT's Q1/26 saw 7.8% revenue growth, with medical devices leading, but operating income ...

Abbott Laboratories’ stock took a direct hit, wiping out nearly 10% of its market value following its Q4 earnings. Response? The CEO bought $2 million shares. Robert B. Ford, CEO of Abbott ...

The one-year data showed that over 98% of patients remained free from ischemic stroke or systemic embolism. Also, more than 99% of patients were free from pericardial effusion that required ...

Abbott Laboratories must pay $53 million in compensatory damages in four cases in which Chicago area babies developed a dangerous intestinal disease after consuming the company's formula for premature ...